Safety of Minimally Invasive Surgery Using Endoscopic Stapler in Early Stage Cervical Cancer Patients (SOLUTION)

Inclusion Criteria: * Females, aged 20 years or older * Histologically confirmed primary squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma of the uterine cervix * Patients with FIGO stage IB1 (FIGO staging 2009) : stromal invasion\>5 mm or 7 mm \<lesion size ≤4 cm * Patients undergoing either type B or C hysterectomy (Querleu-Morrow classification) * Patients with normal bone marrow, renal and hepatic function * WBC \> 3.0x10\^9 cells/L * Platelets \> 100x10\^9 cells/L * Serum creatinine ≤1.5 mg/dL * Serum total bilirubin \<1.5 x normal range and AST/SGOT or ALT/SGPT \<3 x normal range * ECOG performance status 0 or 1 * Synchronous cancer with no evidence of recurrence during the past 5 years * Informed consent of patient Exclusion Criteria: * Any histological type other than squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma of the uterine cervix * Tumor size greater than 4 cm * Patients with FIGO less than stage IA2 or greater than IB2 (FIGO staging 2009) * stromal invasion ≤5 mm and lesion size ≤7 mm (less than IA2) * or lesion size\> 4 cm (greater than IB2) * Patients with evidence of metastatic disease by conventional imaging studies, enlarged pelvic or aortic lymph nodes greater than 2 cm, or histologically positive lymph nodes * Patients in pregnancy * Patients with a history of pelvic or abdominal radiotherapy * Patients with contraindication of surgery (serious concomitant systemic disorders incompatible with the study to be decided at the discretion of the investigator) * Patients who agree to intra-operative lymphatic mapping (IOLM) must not have: * Known allergies to triphenylmethane compounds * History of retroperitoneal surgery. * History of pelvic irradiation. * Cold knife or LEEP cone biopsy within 4 weeks of enrollment